Reading PSTV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PSTV free→Reading PSTV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PSTV free→QuarterlyIQ Insights · PSTV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On June 1, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time (the “Offering”), shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17,350,000 (the “Shares”), depending on market demand, with the Agent…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Eric J. Daniels, M.D. as Chief Development Officer On April 9, 2026, Plus Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Eric J. Daniels as Chief Development Officer of the Company, effective April 20, 2026. Dr. Daniels, age 53, will be responsible for the development and ultimate approval of the Company’s pharma…
of Form 8-K, the information regarding the Reverse Stock Split (as defined herein) contained in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment to Board of Directors On March 20, 2026, the Board of Directors (the “Board”) of Plus Therapeutics, Inc. (the “Company”) unanimously appointed Mr. Ronald A. Andrews to serve as a director of the Board, effective immediately. Mr. Andrews is being appointed to the Board to fill the vacancy created by the resignation of Dr. Robert Lenk and…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 9, 2026, Plus Therapeutics, Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-292637) with the Securities and Exchange Commission (as amended, the “Registration Statement”). Pursuant to Instruction 1 to Item 402(c)(2)(iii) and (iv) of Regulation S-K, the “Summary Compensation Table for 2025 and 2024” included…
Entry into a Material Definitive Agreement. On January 13, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as the underwriter (the “Underwriter”), pursuant to which the Company (a) agreed to issue and sell, in an underwritten public offering (the “Offering”), an aggregate of (i) 39,473,684 shares of common stock, par value $ 0.001 per share (the “Common Stock”), of the Company and (ii) w…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth above under
Entry into a Material Definitive Agreement. On October 16, 2025, Plus Therapeutics, Inc. (the “Company”) entered into a lease (the “Lease”) with LG 1 Property Owner LP, pursuant to which the Company has agreed to lease approximately 11,370 rentable square feet of space located at 6420 Levit Green Boulevard, Houston, Texas 77021. The Lease is expected to commence on or about November 1, 2026. The Lease provides for a monthly base rent of $58,745, which increases annually by approximately 3%, p…
Other Events. On August 22, 2025, Plus Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming its compliance with Nasdaq Listing Rule 5550(b). Specifically, the Letter confirms that the Company is in compliance with both (1) the Market Value of Listing Securities (“MVLS”) standard under 5550(b)(2), which requires certain companies to maintain a market value of listed securities of at least $35 million (the “MVLS Standard”), a…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On July 16, 2025, the audit committee (the “ Audit Committee ”) of the board of directors of Plus Therapeutics, Inc. (the “ Company ”) dismissed BDO USA, P.C. (“ BDO ”) as the Company’s independent registered public accounting firm. BDO’s audit reports on the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain…
Entry into Material Definitive Agreement. On June 17, 2025, Plus Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $50 million of the Company’s common stock, $0.001 par value per share. Under the terms and subject to the conditions of the Purchase Agreement, t…
In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)). The securities referred to in this current report on Form 8-K are being issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Secu…
Material Modification to Rights of Security Holders. To the extent required, the information contained in
Entry into a Material Definitive Agreement. As previously disclosed, on March 4, 2025, Plus Therapeutics, Inc. (the “Company”) entered into that certain Securities Purchase Agreement, dated March 4, 2025 (the “Purchase Agreement”), with the various purchasers party thereto (the “Purchasers”), pursuant to which the Company issued to such Purchasers in an private placement (the “March 2025 Private Placement”) the following securities of the Company: (i) an aggregate of 4,069,738 shares (the “Pr…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 3, 2025, Plus Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the Rule 5250(c)(1) due to filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”) with the U.S. Securities and Exc…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 21, 2025, Plus Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 16, 2025, Plus Therapeutics, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”).…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment to Board of Directors On April 18, 2025, the Board of Directors (the “Board”) of Plus Therapeutics, Inc (the “Company”) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately. Mr. Guse is being appointed to the Board to fill the vacancy created by the resignation of Mr. Greg Petersen, and is expec…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Regulation FD Disclosure. On February 18, 2025, the Company issued a press release announcing the private placement and exchange described above and a $2.0 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), as part of its existing $17.6 million grant.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.